ArticleNPJ Parkinson's disease2026
Perivascular spread of CSF-derived α-synuclein oligomers drives region-specific Parkinson's-like pathology.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
While the level of α-synuclein oligomers (α-SOs) in the CSF of patients with Parkinson's disease (PD) is consistently increased, its pathogenic role in PD remains poorly understood. This study focuses on the role of CSF-derived α-SOs in PD pathology. We demonstrated that CSF-derived α-synuclein enters the brain via perivascular spaces, which was more abundant in the olfactory bulb (OB) than in the substantia nigra (SN). We also found that neuroinflammation was more pronounced in the OB than in the SN following α-SOs injection. α-SOs-treated mice exhibited an early and persistent loss of dopaminergic (DA) neurons in the OB, along with olfactory deficit. Conversely, DA neuron loss in the SN occurred later and was associated with motor dysfunction. Furthermore, reducing α-SOs dose alleviated OB pathology. These findings suggest that perivascular spread of CSF-derived α-SOs induces region-specific PD-like pathology, indicating that removing CSF-derived α-SOs could slow PD progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.